Payment overview · 2025
General Payments
$3,880.38
80 reported records · 15 companies
Healthcare provider profile · identity verified
Raja Naidu, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ODESSA, TX · NPI 1124095161
Verified facts
What the public records show
CMS Open Payments records show Raja Naidu, MD received $3,880.38 in general payments during 2025 across 80 reported records.
ABIOMED accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $1,535.92 | 39.6% | 13 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $784.12 | 20.2% | 14 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $371.98 | 9.6% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$284.23 | 7.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $267.70 | 6.9% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $164.85 | 4.2% | 9 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $114.99 | 3.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.55 | 2.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $77.55 | 2.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.29 | 1.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.35 | 1.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.33 | 1.0% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $15.54 | 0.4% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $13.70 | 0.3% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $13.28 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,465.17 | 75 |
| Travel and Lodging | $1,394.99 | 4 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $443.19 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $371.98 | 4 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $274.98 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $267.70 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $164.85 | 9 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $122.80 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $114.99 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.55 | 4 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $75.22 | 4 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $61.69 | 1 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $59.71 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.29 | 3 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $48.05 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.35 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| CROME DR MRI SURESCAN Normalized: crome dr mri surescan |
Device | Medtronic, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross Normalized: opticross |
Device | Boston Scientific Corporation | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $13.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
214 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 823 | 240 |
| Eliquis | Apixaban | 559 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 167 |
| Furosemide | Furosemide | 486 | 157 |
| Losartan Potassium | Losartan Potassium | 476 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 137 |
| Metoprolol Tartrate | Metoprolol Tartrate | 419 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 397 | 122 |
| Amiodarone Hcl | Amiodarone Hcl | 289 | 90 |
| Lisinopril | Lisinopril | 265 | 80 |
| Carvedilol | Carvedilol | 253 | 74 |
| Doxazosin Mesylate | Doxazosin Mesylate | 220 | 73 |
| Entresto | Sacubitril/Valsartan | 214 | 42 |
| Potassium Chloride | Potassium Chloride | 210 | 67 |
| Alprazolam | Alprazolam | 193 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 138 | 39 |
| Bumetanide | Bumetanide | 134 | 46 |
| Mounjaro | Tirzepatide | 131 | 24 |
| Xarelto | Rivaroxaban | 129 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 32 |
| Temazepam | Temazepam | 105 | 23 |
| Gabapentin | Gabapentin | 101 | 24 |
| Metformin Hcl | Metformin Hcl | 93 | 31 |
| Simvastatin | Simvastatin | 83 | 24 |
| Nitroglycerin | Nitroglycerin | 79 | 41 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 18 |
| Spironolactone | Spironolactone | 75 | 25 |
| Repatha Sureclick | Evolocumab | 69 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 20 |
| Tramadol Hcl | Tramadol Hcl | 67 | 21 |
| Brilinta | Ticagrelor | 66 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 11 |
| Clonidine Hcl | Clonidine Hcl | 55 | 15 |
| Valsartan | Valsartan | 52 | 13 |
| Warfarin Sodium | Warfarin Sodium | 51 | 15 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 38 | suppressed |
| Digoxin | Digoxin | 37 | 11 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Atenolol | Atenolol | 31 | 11 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Omeprazole | Omeprazole | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,880.38 · 80 records | ABIOMED | AVVIGO Guidance System, AZURE XT DR MRI SURESCAN, Barostim Neo System, CARDIOMEMS, COBALT DR MRI SURESCAN, CROME DR MRI SURESCAN, FARXIGA, GUIDELINER, General - Balloon Catheters, General - Vascular Access, JARDIANCE, Kerendia, LEQVIO, Omnipod, OptiCross, REPATHA, RHYTHM EXPRESS, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, ULTREON, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error